These results are especially relevant in early-stage ERBB2/HER2-positive breast cancer, in which multiple trials focus on developing prognostic tools combining tumor and immune cell biomarkers to guide treatment escalation and de-escalation.25,41,42,43. This evidence concerns the gene ERBB2 and breast carcinoma.